Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics, Inc. (TVTX)
NASDAQ:TVTX
TVTX Stock Chart & Stats
$29.71
-$0.11(-0.58%)
At close: 4:00 PM EST
$29.71
-$0.11(-0.58%)
Day’s Range― - ―
52-Week Range$12.91 - $42.13
Previous CloseN/A
Volume140.04K
Average Volume (3M)2.48M
Market Cap
$2.66B
Enterprise Value$2.89B
Total Cash (Recent Filing)$254.53M
Total Debt (Recent Filing)$329.75M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Feb 19, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding89,472,330
10 Day Avg. Volume1,571,999
30 Day Avg. Volume2,476,439
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)23.26
Price to Sales (P/S)5.89
P/FCF Ratio-4.06
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue6.63
Enterprise Value/Gross Profit6.79
Enterprise Value/Ebitda-127.96
Forecast
1Y Price Target
$42.25Price Target Upside42.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)0.85
Revenue Forecast (FY)$690.40M
Bulls Say, Bears Say
Bulls Say
Analyst Confidence And Balance SheetAnalyst maintains a Buy rating with a high risk designation, citing robust IgAN performance and a substantial cash position that supports operational flexibility.
Commercial TractionStrong Filspari sales growth in IgA nephropathy and clear adoption among nephrologists support ongoing market momentum and provide downside support while regulatory matters are resolved.
Regulatory SignalFDA extension of the PDUFA review without requests for additional safety or manufacturing data signals constructive regulator engagement and preserves a credible path to approval.
Bears Say
Clinical Trial UncertaintyThe pivotal late‑stage trial missed its primary endpoint on long‑term kidney function, creating uncertainty about the supplemental application and the likelihood of approval.
Regulatory Timing And VolatilityRegulators classified company responses as a major amendment and extended the review, increasing the risk of delayed approval, greater stock volatility, and the possibility of requests for additional studies.
Revenue PressurePre‑reported product sales came in slightly below expectations, prompting cuts to sales and royalty assumptions that could weigh on near‑term revenue forecasts.
Travere Therapeutics News
TVTX FAQ
What was Travere Therapeutics, Inc.’s price range in the past 12 months?
Travere Therapeutics, Inc. lowest stock price was $12.91 and its highest was $42.13 in the past 12 months.
What is Travere Therapeutics, Inc.’s market cap?
Travere Therapeutics, Inc.’s market cap is $2.66B.
When is Travere Therapeutics, Inc.’s upcoming earnings report date?
Travere Therapeutics, Inc.’s upcoming earnings report date is Feb 19, 2026 which is in 9 days.
How were Travere Therapeutics, Inc.’s earnings last quarter?
Travere Therapeutics, Inc. released its earnings results on Oct 30, 2025. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of -$0.304 by $0.584.
Is Travere Therapeutics, Inc. overvalued?
According to Wall Street analysts Travere Therapeutics, Inc.’s price is currently Undervalued.
Does Travere Therapeutics, Inc. pay dividends?
Travere Therapeutics, Inc. does not currently pay dividends.
What is Travere Therapeutics, Inc.’s EPS estimate?
Travere Therapeutics, Inc.’s EPS estimate is <0.01.
How many shares outstanding does Travere Therapeutics, Inc. have?
Travere Therapeutics, Inc. has 89,472,330 shares outstanding.
What happened to Travere Therapeutics, Inc.’s price movement after its last earnings report?
Travere Therapeutics, Inc. reported an EPS of $0.28 in its last earnings report, beating expectations of -$0.304. Following the earnings report the stock price went up 18.583%.
Which hedge fund is a major shareholder of Travere Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TVTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.25 (42.21% Upside)
$42.25 (42.21% Upside)
Blogger Sentiment
Bullish
TVTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.91%
12-Months-Change
Fundamentals
Return on Equity
-410.78%
Trailing 12-Months
Asset Growth
6.77%
Trailing 12-Months
Company Description
Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
TVTX Company Deck
TVTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong quarter characterized by significant growth in FILSPARI sales, potential FDA approval for new indications, and successful manufacturing advancements. However, seasonal trends and a competitive market present challenges.View all TVTX earnings summariesTVTX Stock 12 Month Forecast
Average Price Target
$42.25
▲(42.21% Upside)
Technical Analysis
Galapagos
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
1.49% Insiders
31.01% Mutual Funds
0.64% Other Institutional Investors
49.21% Public Companies and
Individual Investors